Best Peptides for Joint Pain, Ranked by Human Evidence

Collagen peptides and undenatured type II collagen have human trials for joint pain. BPC-157 and TB-500 rest on animal data. Ranked by human evidence.

Written bySebastian Hunter, Founder and EditorI'm a 42-year-old senior advisor and distance runner who came to peptides as a sceptic. I'm not a doctor: I read the research, run my own experiment and keep honest notes. Read full bio

Published October 3, 2026

The short version

Oral collagen supplements are the only peptides with a real trial record for joint pain. Dozens of randomised trials, mostly in knee osteoarthritis, show small to moderate improvements in pain and function. BPC-157 and TB-500, the injectables sold most often for joints, have been studied mainly in rats. In people, BPC-157 has one 17-patient chart review for knee pain, and TB-500 has no published study at all.

Collagen peptides and undenatured type II collagen have randomised trials for joint pain, with modest effects.
The only human joint study of BPC-157 is an uncontrolled chart review of 17 knee-pain patients.
FDA found no clinical study or human exposure data for TB-500 by any route.
This is a ranking of evidence, not a recommendation to take anything.

The peptides with real human trials for joint pain are oral collagen peptides and undenatured type II collagen, both sold as supplements. BPC-157 and TB-500, the injectables sold most often for joints, have animal data and almost no human data.

Collagen peptides are short chains of amino acids cut from collagen protein and taken by mouth, so they belong on this list. The ranking orders each option by the strongest human evidence behind it. A higher rank means more and better trials, not a promise of relief, and even the top entry shows modest effects.

The ranking at a glance

Rank	Compound	Human evidence	What was measured	US legal status	Read more
1	Collagen peptides (hydrolysed collagen)	Many randomised trials, pooled in meta-analyses	Pain and function in osteoarthritis; activity-related joint pain in athletes	Dietary supplement	Collagen for joints
2	Undenatured type II collagen (UC-II)	Several randomised trials, including one of 191 people	Pain, stiffness and function scores in knee osteoarthritis	Dietary supplement	Collagen for joints
3	BPC-157	One uncontrolled chart review of 17 knee-pain patients	Pain relief recalled by phone	Not FDA-approved; sold as a research chemical	BPC-157
4	TB-500	No published human study found	Tendon healing in rats only	Not FDA-approved; sold as a research chemical	TB-500

1. Collagen peptides: the most trials, modest effects

Moderate human evidence

Multiple randomised trials, though with limitations. Dozens of randomised trials in osteoarthritis, pooled in meta-analyses that report small-to-moderate improvements in pain and function. Older reviews rated much of the evidence very low quality.

Hydrolysed collagen, sold as collagen peptides, has the largest trial record of anything on this page. A 2024 meta-analysis pooled 35 randomised trials of collagen products in osteoarthritis, with 3,165 patients (Liang 2024 - Liang CW, Cheng HY, Lee YH et al. Efficacy and safety of collagen derivatives for osteoarthritis: A trial sequential meta-analysis. Osteoarthritis Cartilage. 2024;32(5):574-584., in the references below). Compared with control, pain and function improved, and side effects did not increase. The authors called the effects small to moderate.

An earlier review of 69 supplement trials for osteoarthritis found large short-term pain effects for collagen hydrolysate, based on few studies. It rated the overall evidence very low quality (Liu 2018 - Liu X, Machado GC, Eyles JP et al. Dietary supplements for treating osteoarthritis: a systematic review and meta-analysis. Br J Sports Med. 2018;52(3):167-175., in the references below). No supplement in that review had a clinically important effect on pain in the long term.

The best-known trial outside osteoarthritis is in athletes. It enrolled 147 varsity and club athletes with activity-related joint pain and no joint disease. Over 24 weeks, 10 g of collagen hydrolysate a day reduced several pain scores more than placebo (Clark 2008 - Clark KL, Sebastianelli W, Flechsenhar KR et al. 24-Week study on the use of collagen hydrolysate as a dietary supplement in athletes with activity-related joint pain. Curr Med Res Opin. 2008;24(5):1485-96., in the references below). Only 97 of the 147 could be analysed.

Collagen peptides are dietary supplements. FDA does not approve supplements before they go on sale, and a supplement sold to treat a disease counts legally as a drug. More detail, including how to read a collagen trial: collagen peptides for joints.

2. Undenatured type II collagen: a different product at a far smaller dose

Moderate human evidence

Multiple randomised trials, though with limitations. Several randomised trials in knee osteoarthritis, including a 191-person trial against placebo and against glucosamine with chondroitin. Two of that trial's three authors worked for the supplement's maker.

Undenatured type II collagen, often sold as UC-II, is made from chicken sternum cartilage and taken in milligrams, not grams. As the name says, it is not broken down into peptides. It is here because it is sold for the same job, and the results of one product don’t transfer to the other.

Its main trial randomised 191 people with knee osteoarthritis to 40 mg of UC-II a day, glucosamine with chondroitin, or placebo for 180 days (Lugo 2016 - Lugo JP, Saiyed ZM, Lane NE. Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: a multicenter randomized, double-blind, placebo-controlled study. Nutr J. 2016;15:14., in the references below). UC-II lowered the total WOMAC score more than placebo and more than glucosamine with chondroitin. WOMAC is a standard scale of osteoarthritis pain, stiffness and function. Two of the three authors worked for the supplement’s maker, InterHealth Nutraceuticals.

In the 69-trial review, UC-II improved pain in the short term by a statistically significant amount of unclear clinical importance. It was one of only two supplements with a clinically important effect at medium term (Liu 2018 - Liu X, Machado GC, Eyles JP et al. Dietary supplements for treating osteoarthritis: a systematic review and meta-analysis. Br J Sports Med. 2018;52(3):167-175., in the references below). I rank it second because it has fewer trials than collagen peptides, not because its results are weaker.

3. BPC-157: consistent in rats, one small chart review in people

Limited human data

Small or uncontrolled human studies. Too little to settle the question either way. Five small published human studies, with about 80 people given BPC-157. The only one about joints is a retrospective chart review of 17 knee-pain patients with no comparison group. Animal studies of tendon and ligament healing are consistently positive.

BPC-157 is the peptide most often sold for joints and tendons, and its animal record is the reason. A review of tendon, ligament and muscle studies found consistently positive healing results, mostly in small rodents. It noted that benefit in humans has not been confirmed (Gwyer 2019 - Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159., in the references below).

The only joint study in people is a retrospective chart review from a Florida clinic (Lee 2021 - Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13., in the references below). Of 16 knee-pain patients reached by phone, 11 of the 12 given BPC-157 alone (injected into the knee) said their pain had improved significantly. There was no comparison group and no standard pain scale. Most injections had been given 6 to 12 months earlier.

FDA’s July 2026 briefing lists five published human studies of BPC-157, with about 80 people given it. The knee review is the only one about joints. FDA also found no human data on how BPC-157 is absorbed after oral, under-the-skin or nasal doses.

BPC-157 is not FDA-approved and is sold as a research chemical. On 23 July 2026, FDA’s compounding advisory committee voted 8-6, with one abstention, to recommend letting pharmacies compound it. As of 3 October 2026, I found no rule in the Federal Register adding it to the compounding list. Common-practice doses are on the BPC-157 dosage page.

4. TB-500: no human study found

Animal / lab only

Studied in cells or animals. No controlled trials in humans. FDA's July 2026 review found no clinical study or human exposure data for TB-500 by any route. The animal evidence is a small number of rat and cell studies.

TB-500 is a synthetic seven-amino-acid piece of thymosin beta-4, a protein the body makes (Esposito 2012 - Esposito S, Deventer K, Goeman J et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-8., in the references below). Research on the whole protein doesn’t automatically apply to the fragment. FDA’s July 2026 review found no clinical study or human exposure data for TB-500 by any route, and I found none either.

Its animal evidence is thin too. In 32 rats with repaired Achilles tendons, TB-500 improved tendon strength and tissue scores at four weeks compared with untreated rats (Biçer 2026 - Biçer O, Adanir O, Güleryüz Y et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837., in the references below). The same 8-6 committee vote recommended TB-500 for compounding, and I found no rule adding it either.

Blends: the Wolverine stack and KLOW

The Wolverine stack is BPC-157 plus TB-500, often sold premixed. No trial has tested the combination in people. In the knee chart review, 4 patients got BPC-157 with thymosin beta-4, and 3 reported relief (Lee 2021 - Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13., in the references below). In the rat Achilles study, the combination did no better than either peptide alone (Biçer 2026 - Biçer O, Adanir O, Güleryüz Y et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837., in the references below).

KLOW adds GHK-Cu and KPV to the same pair. I found no human or animal study of the four combined. More on each: Wolverine stack and the KLOW blend.

Other peptides sold for joints

AOD-9604. The one joint study I found is in rabbits: injections into knees with enzyme-induced osteoarthritis reduced cartilage damage (Kwon 2015 - Kwon DR, Park GY. Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Ann Clin Lab Sci. 2015;45(4):426-32., in the references below). See AOD-9604.
Cartalax. Marketed as a cartilage bioregulator. I found no human study of any kind. See Cartalax.

Neither has the human evidence to enter the ranking.

Common questions

Will BPC-157 help with joint pain?

No trial has shown that it does. The only joint study in people is a Florida clinic's look back at 17 knee-pain patients given BPC-157 injections into the knee. Eleven of the 12 who got BPC-157 alone said by phone, months later, that their pain had improved a lot. There was no comparison group. Rat studies of tendon and ligament healing are consistently positive, and they cannot show what happens in a human knee.

Do peptides really work for joint pain?

Oral collagen peptides have the best evidence. A 2024 meta-analysis of 35 randomised trials in osteoarthritis found small-to-moderate improvements in pain and function compared with control. Injectable research peptides such as BPC-157 and TB-500 have not been tested in a controlled trial for joint pain. Whether they work in people is unknown.

What is the strongest anti-inflammatory peptide?

By volume of human evidence, thymosin alpha-1 ranks first, but its trials tested sepsis, hepatitis B and pancreatitis outcomes rather than joint inflammation. The largest, in 1,106 people with sepsis, found no clear survival benefit. I found no controlled trial showing that any peptide reduces joint inflammation. Our separate ranking of peptides for inflammation covers each one.

Are there oral peptides for joint pain?

Yes. Collagen peptides and undenatured type II collagen are both taken by mouth, and both have trials in osteoarthritis. Oral BPC-157 capsules are also sold. FDA found no human data on how BPC-157 is absorbed when swallowed, and no trial has tested the capsules for joint pain.

How long do collagen supplements take to help joints?

The trials ran for months. The athlete study measured pain over 24 weeks, and the main undenatured type II collagen trial over 180 days. Results were reported at the end of those periods, so the trials say little about what happens in the first few weeks.

Is collagen better than BPC-157 for joint pain?

No trial has compared them. Collagen has randomised trials showing modest benefit in osteoarthritis, and BPC-157 has none for joints. The evidence favours collagen by default, not because of a head-to-head result.

What is the Wolverine stack for joints?

It is BPC-157 combined with TB-500. No trial has tested the combination in people. In the knee chart review, 4 patients got BPC-157 with thymosin beta-4, and 3 reported relief. In a rat study of repaired Achilles tendons, the combination did no better than either peptide alone.

References (14 sources)

Bibliographic detail is fetched from PubMed, not written by me - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than my judgement.